Liquidia Technologies, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2004-01-01
- Employees
- 101
- Market Cap
- $741M
- Website
- http://www.liquidia.com
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Conditions
- Interstitial Lung DiseasePulmonary Hypertension
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06129240
- Locations
- 🇺🇸
The Medical Research Group, Inc., Fresno, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
- Conditions
- Pulmonary Arterial HypertensionPulmonary Hypertension Due to Lung Diseases
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04691154
- Locations
- 🇺🇸
Arizona Pulmonary Specialists, Phoenix, Arizona, United States
🇺🇸VA Greater Los Angeles Healthcare, Los Angeles, California, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- Drug: LIQ861 Inhaled Treprostinil
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT03992755
- Locations
- 🇺🇸
Banner University Medical Center, Phoenix, Arizona, United States
🇺🇸Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States
🇺🇸West Los Angeles VA Healthcare Center, Los Angeles, California, United States
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Inhaled dry powder treprostinil (LIQ861)
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03884465
- Locations
- 🇫🇷
CHRU de Nancy, Nancy, Vandoeuvre Les Nancy, France
🇫🇷CHU de Bicetre, Le Kremlin-Bicêtre, France
🇩🇪Studienambulanz fur Pulmonale Hypertonie at Medizinishe Klinik II, Universitatskinikum Giessen und Marburg GmbH, Gießen, Germany
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- Drug: LIQ861 Inhaled Treprostinil
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03399604
- Locations
- 🇺🇸
Banner University Medical Center, Phoenix, Arizona, United States
🇺🇸Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States
🇺🇸West Los Angeles VA Healthcare Center, Los Angeles, California, United States
- Prev
- 1
- 2
- Next
News
Pipeline for Pulmonary Arterial Hypertension Treatment Expands with 55+ Companies Developing Novel Therapies
DelveInsight's latest report reveals over 55 companies actively developing 55+ pipeline drugs for Pulmonary Arterial Hypertension treatment, indicating robust research activity in this therapeutic area.